The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessAbstract
Two different primary malignancies can arise from the adrenal gland: adrenocortical carcinoma (ACC) from the adrenal cortex and malignant phaeochromocytoma from the adrenal medulla. Both malignancies are rare. ACC has an estimated incidence of ∼0.5-2 new cases per million people per year.1,2 Phaeochromocytomas are catecholamine-producing neuroendocrine tumours arising from chromaffin cells of the adrenal medulla or extra-adrenal paraganglia. The latter are usually called paraganglioma, leading to the combined term phaeochromocytomas and paragangliomas (PPGLs).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Self-citationWHO Classification of Tumours of Endocrine Organs
김나래, Lloyd, Osamura, Rosai, & Klöppel, G. (2017) · Medical Entomology and Zoology · Cited by 1,600
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566 · cited 1×
“measuring plasma-free or urinary-fractionated metanephrines [V, A].(5,10) Additional measurements of plasma methoxytyramine, a biomarker now increasingly available, provide useful information to assess the likelihood of malignancy.”
BackgroundSelf-citationFassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Self-citationComparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 873
Self-citationPathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
SDH mutations establish a hypermethylator phenotype in paraganglioma
Letouzé, E., Martinelli, C., Loriot, C., Burnichon, N., Abermil, N., Ottolenghi, C., Janin, M., Menara, M., Nguyen, A. T., Benit, P., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.018 · Cited by 776 · cited 1×
“Inactivation of SDHB reduces function of the succinate dehydrogenase complex, leading to activation of the hypoxia-inducible pathway and a pseudohypoxic state characterised by increased angiogenesis, growth and expression of mitogenic factors,(26) but also to DNA hypermethylation, which is believed to provide a furthe…”
BackgroundAdjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 764
Self-citationThompson, L. D. R. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200205000-00002 · Cited by 715
Fassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citationGenetic Testing in Pheochromocytoma or Functional Paraganglioma
Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O., Chamontin, B., Delemer, B., Giraud, S., Murat, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1484 · Cited by 684
Self-citationPheochromocytoma: recommendations for clinical practice from the First International Symposium
Pacak, K., Eisenhofer, G., Ahlman, H., Bornstein, S. R., Gimenez-Roqueplo, A.-P., Grossman, A. B., Kimura, N., Mannelli, M., McNicol, A. M., & Tischler, A. S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0396 · Cited by 680
Self-citationDykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
Dahia, P. L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3648 · Cited by 545
Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C. (2008) · Cancer · doi:10.1002/cncr.23886 · Cited by 493
Plouin, P. F., Amar, L., Dekkers, O. M., Fassnacht, M., Gimenez-Roqueplo, A. P., Lenders, J. W. M., Lussey-Lepoutre, C., Steichen, O., & _, _. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0033 · Cited by 480
Self-citationUrine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors
Arlt, W., Biehl, M., Taylor, A. E., Hahner, S., Libé, R., Hughes, B. A., Schneider, P., Smith, D. J., Stiekema, H., Krone, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1565 · Cited by 458
Self-citationExtent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
Kebebew, E., Reiff, E., Duh, Q., Clark, O. H., & McMillan, A. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0329-x · Cited by 451
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma
Kimura, N., Takayanagi, R., Takizawa, N., Itagaki, E., Katabami, T., Kakoi, N., Rakugi, H., Ikeda, Y., Tanabe, A., Nigawara, T., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0494 · Cited by 393
Amar, L., Servais, A., Gimenez-Roqueplo, A.-P., Zinzindohoue, F., Chatellier, G., & Plouin, P.-F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1398 · Cited by 390
Kerkhofs, T. M. A., Verhoeven, R. H. A., Van der Zwan, J. M., Dieleman, J., Kerstens, M. N., Links, T. P., Van de Poll-Franse, L. V., & Haak, H. R. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.034 · Cited by 341
Self-citationFassnacht, M., Berruti, A., Baudin, E., Demeure, M. J., Gilbert, J., Haak, H., Kroiss, M., Quinn, D. I., Hesseltine, E., Ronchi, C. L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70081-1 · Cited by 339
Self-citationEisenhofer, G., Lenders, J. W. M., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., Mannelli, M., Linehan, W. M., Adams, K., Timmers, H. J., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.07.016 · Cited by 334
Self-citationNew Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
Pryma, D. A., Chin, B. B., Noto, R. B., Dillon, J. S., Perkins, S. M., Sólnes, L. B., Kostakoğlu, L., Serafini, A. N., Pampaloni, M. H., Jensen, J., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.217463 · Cited by 320
Brouwers, F. M., Eisenhofer, G., Tao, J. J., Kant, J. A., Adams, K. T., Linehan, W. M., & Pacak, K. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0423 · Cited by 316
Self-citationBerruti, A., Terzolo, M., Sperone, P., Pia, A., Della Casa, S., Gross, D. J., Carnaghi, C., Casali, P., Porpiglia, F., Mantero, F., et al. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01025 · Cited by 308
Self-citationThe NGS in PPGL (NGSnPPGL) Study Group, Toledo, R. A., Burnichon, N., Cascon, A., Benn, D. E., Bayley, J.-P., Welander, J., Tops, C. M., Firth, H., Dwight, T., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.185 · Cited by 275
Libé, R., Borget, I., Ronchi, C. L., Zaggia, B., Kroiss, M., Kerkhofs, T., Bertherat, J., Volante, M., Quinkler, M., Chabre, O., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv329 · Cited by 263
Self-citationGonias, S., Goldsby, R., Matthay, K. K., Hawkins, R., Price, D., Huberty, J., Damon, L., Linker, C., Sznewajs, A., Shiboski, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3496 · Cited by 245
Gaujoux, S., Mihai, R., Carnaille, B., Dousset, B., Fiori, C., Porpiglia, F., Hellman, P., Iacobone, M., Kraimps, J.-L., Donatini, G., et al. (2017) · British Journal of Surgery · doi:10.1002/bjs.10414 · Cited by 226
Self-citationDinnes, J., Bancos, I., Ferrante di Ruffano, L., Chortis, V., Davenport, C., Bayliss, S., Sahdev, A., Guest, P., Fassnacht, M., Deeks, J. J., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0461 · Cited by 219
Self-citationAyala-Ramirez, M., Chougnet, C. N., Habra, M. A., Palmer, J. L., Leboulleux, S., Cabanillas, M. E., Caramella, C., Anderson, P., Al Ghuzlan, A., Waguespack, S. G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2356 · Cited by 212
Self-citationHadoux, J., Favier, J., Scoazec, J., Leboulleux, S., Al Ghuzlan, A., Caramella, C., Déandreis, D., Borget, I., Loriot, C., Chougnet, C., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28913 · Cited by 210
Self-citationHan, S., Suh, C. H., Woo, S., Kim, Y. J., & Lee, J. J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.211706 · Cited by 205
Park, H. S. (2009) · Archives of Surgery · doi:10.1001/archsurg.2009.191 · Cited by 201
PD-1 Blockade in Advanced Adrenocortical Carcinoma
Raj, N., Zheng, Y., Kelly, V., Katz, S. S., Chou, J., Do, R. K. G., Capanu, M., Zamarin, D., Saltz, L. B., Ariyan, C. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01586 · Cited by 200
Faßnacht, M., Johanssen, S., Fenske, W. K., Weismann, D., Agha, A., Beuschlein, F., Führer, D., Jurowich, C. F., Quinkler, M. O., Petersenn, S., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0803 · Cited by 182
Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma
Reibetanz, J., Jurowich, C., Erdogan, I., Nies, C., Rayes, N., Dralle, H., Behrend, M., Allolio, B., & Fassnacht, M. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182367ac3 · Cited by 176
Le Tourneau, C., Hoimes, C., Zarwan, C., Wong, D. J., Bauer, S., Claus, R., Wermke, M., Hariharan, S., von Heydebreck, A., Kasturi, V., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0424-9 · Cited by 173
Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction
Jochmanova, I., Yang, C., Zhuang, Z., & Pacak, K. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt201 · Cited by 172
Sperone, P., Ferrero, A., Daffara, F., Priola, A., Zaggia, B., Volante, M., Santini, D., Vincenzi, B., Badalamenti, G., Intrivici, C., et al. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0281 · Cited by 167
Self-citationAyala‐Ramirez, M., Feng, L., Habra, M. A., Rich, T., Dickson, P. V., Perrier, N., Phan, A., Waguespack, S., Patel, S., & Jimenez, C. (2012) · Cancer · doi:10.1002/cncr.26577 · Cited by 161
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Habra, M. A., Stephen, B., Campbell, M., Hess, K., Tapia, C., Xu, M., Rodon Ahnert, J., Jimenez, C., Lee, J. E., Perrier, N. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0722-x · Cited by 160
Adverse Drug Reactions in Patients with Phaeochromocytoma: Incidence, Prevention and Management
Eisenhofer, G., Rivers, G., Rosas, A. L., Quezado, Z., Manger, W. M., & Pacák, K. (2007) · Drug Safety · doi:10.2165/00002018-200730110-00004 · Cited by 158
Self-citationPrognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer
Berruti, A., Fassnacht, M., Haak, H., Else, T., Baudin, E., Sperone, P., Kroiss, M., Kerkhofs, T., Williams, A. R., Ardito, A., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.006 · Cited by 158
Self-citationThe role of surgery in the management of recurrent adrenocortical carcinoma
Erdogan, I., Deutschbein, T., Jurowich, C., Kroiss, M., Ronchi, C., Quinkler, M., Waldmann, J., Willenberg, H. S., Beuschlein, F., Fottner, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2559 · Cited by 154 · cited 1×
“In case of a recurrence following ACC surgery, two critical questions must be addressed: (i) What is the time interval since the resection? and (ii) Did recurrence occur during ongoingmitotane therapy (with effective blood levels)? If the disease-free interval is at least 12 months and another complete R0 resection/ab…”
BackgroundBerruti, A., Grisanti, S., Pulzer, A., Claps, M., Daffara, F., Loli, P., Mannelli, M., Boscaro, M., Arvat, E., Tiberio, G. A. M., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2894 · Cited by 141
Self-citationCrona, J., Lamarca, Á., Ghosal, S., Welin, S., Skogseid, B. M., & Pacák, K. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0024 · Cited by 140
Terzolo, M., Baudin, A. E., Ardito, A., Kroiss, M., Leboulleux, S., Daffara, F., Perotti, P., Feelders, R. A., deVries, J. H., Zaggia, B., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0242 · Cited by 134 · cited 1×
“Another retrospective multicentre study demonstrated that blood mitotane concentrations 14 mg/l were associated with a prolonged RFS in patients treated with adjuvantmitotane followingmacroscopically radical surgery.(54) On these bases, the recent ESEeENSAT guidelines on the management of ACC suggest that patients at…”
Self-citationAyala‐Ramirez, M., Palmer, J. L., Hofmann, M.-C. C., de la Cruz, M., Moon, B. S., Waguespack, S. G., Habra, M. A., & Jiménez, C. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4231 · Cited by 134
Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial
Carneiro, B. A., Konda, B., Costa, R. B., Costa, R. L. B., Sagar, V., Gursel, D. B., Kirschner, L. S., Chae, Y. K., Abdulkadir, S. A., RADEMAKER, A. W., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00600 · Cited by 132
Hescot, S., Leboulleux, S., Amar, L., Vezzosi, D., Borget, I., Bournaud, C., de la Fouchardière, C., Libé, R., Cao, C. D., Niccoli, P., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1907 · Cited by 123
Román-Gonzaléz, A., Zhou, S., Ayala‐Ramirez, M., Shen, C., Waguespack, S. G., Habra, M. A., Karam, J. A., Perrier, N. D., Wood, C. G., & Jiménez, C. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000002195 · Cited by 119
Koh, J.-M., Ahn, S. H., Kim, H., Kim, B.-J., Sung, T.-Y., Kim, Y. H., Hong, S. J., Song, D. E., & Lee, S. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187398 · Cited by 114
Hines, J. M., Bancos, I., Bancos, C., Singh, R. D., Avula, A. V., Young, W. F., Grebe, S. K., & Singh, R. J. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.271106 · Cited by 111
Henning, J. E. K., Deutschbein, T., Altieri, B., Steinhauer, S., Kircher, S., Sbiera, S., Wild, V., Schlötelburg, W., Kroiß, M., Perotti, P., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01624 · Cited by 111
Self-citationBukowski, R. M., Wolfe, M., Levine, H. S., Crawford, D., Stephens, R. L., Gaynor, E. R., & Harker, W. G. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.161 · Cited by 110
Williamson, S. K., Lew, D. L., Miller, G. J., Balcerzak, S. P., Baker, L. H., & Crawford, E. D. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5<1159::aid-cncr28>3.0.co;2-r · Cited by 109
A 13-steroid serum panel based on LC-MS/MS: use in detection of adrenocortical carcinoma
Taylor, D. R., Ghataore, L., Couchman, L., Vincent, R. P., Whitelaw, B., Lewis, D., Diaz-Cano, S., Galata, G., Schulte, K.-M., Aylwin, S., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.277624 · Cited by 109
Diagnostic value of urinary steroid profiling in the evaluation of adrenal tumors
Kerkhofs, T. M. A., Kerstens, M. N., Kema, I. P., Willems, T. P., & Haak, H. R. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0224-3 · Cited by 102
Self-citationOperative management for recurrent and metastatic adrenocortical carcinoma
Datrice, N., Langan, R. C., Ripley, R. T., Kemp, C. D., Steinberg, S. M., Wood, B. J., Libutti, S. K., Fojo, T., Schrump, D. S., & Avital, I. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.23015 · Cited by 100
Adrenocortical carcinoma: effect of hospital volume on patient outcome
Lombardi, C. P., Raffaelli, M., Boniardi, M., Toma, G. D., Marzano, L. A., Miccoli, P., Minni, F., Morino, M., Pelizzo, M. R., Pietrabissa, A., et al. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0866-8 · Cited by 97
Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma
Favier, J., Igaz, P., Burnichon, N., Amar, L., Libé, R., Badoual, C., Tissier, F., Bertherat, J. Y., Plouin, P., Jeunemaître, X., et al. (2011) · Endocrine Pathology · doi:10.1007/s12022-011-9189-0 · Cited by 95
Postlewait, L. M., Ethun, C. G., Tran, T. B., Prescott, J. D., Pawlik, T. M., Wang, T. S., Glenn, J. A., Hatzaras, I. S., Shenoy, R. S., Phay, J. E., et al. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2015.12.013 · Cited by 92
Vanbrabant, T., Fassnacht, M., Assie, G., & Dekkers, O. M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0450 · Cited by 91
Pierre, C., Agopiantz, M., Brunaud, L., Battaglia-Hsu, S.-F., Max, A., Pouget, C., Nominé-Criqui, C., Lomazzi, S., Vignaud, J.-M., Weryha, G., et al. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02553-5 · Cited by 89
Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma
Schweitzer, S., Kunz, M., Kurlbaum, M., Vey, J., Kendl, S., Deutschbein, T., Hahner, S., Fassnacht, M., Dandekar, T., & Kroiss, M. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0782 · Cited by 85
Neumann, H. P. H., Young, W. F., Krauß, T., Bayley, J., Schiavi, F., Opocher, G., Boedeker, C. C., Tirosh, A., Castinetti, F., Ruf, J., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0085 · Cited by 82
Baudin, É. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.03.001 · Cited by 79
Tang, Y., Liu, Z., Zou, Z., Liang, J., Lu, Y., & Zhu, Y. (2018) · BioMed Research International · doi:10.1155/2018/9362108 · Cited by 77
Borderline Resectable Adrenal Cortical Carcinoma: A Potential Role for Preoperative Chemotherapy
Bednarski, B. K., Habra, M. A., Phan, A. T., Milton, D. R., Wood, C. G., Vauthey, N., Evans, D. B., Katz, M. H. G., Ng, C. S., Perrier, N. D., et al. (2014) · World Journal of Surgery · doi:10.1007/s00268-014-2484-4 · Cited by 72
Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany
Johanssen, S., Hahner, S., Saeger, W., Quinkler, M. O., Beuschlein, F., Dralle, H., Haaf, M., Kroiß, M., Jurowich, C. F., Langer, P., et al. (2010) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2010.0885 · Cited by 71
Kerkhofs, T. M. A., Verhoeven, R. H. A., Bonjer, H. J., van Dijkum, E. J. M. N., Vriens, M. R., de Vries, J., van Eijck, C. H. J., Bonsing, B. A., van de Poll-Franse, L. V., Haak, H. R., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0142 · Cited by 67
Self-citationAdvanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
Megerle, F., Kroiß, M., Hahner, S., & Faßnacht, M. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1946 · Cited by 58
Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?
Baudin, É., Leboulleux, S., Ghuzlan, A. A., Chougnet, C., Young, J., Deandreis, D., Dumont, F., Dechamps, F., Caramella, C., Chanson, P., et al. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0094-2 · Cited by 47
Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.
Hermsen, I. G. C., Gelderblom, H. A. J., Kievit, J., Romijn, J. A., & Haak, H. R. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0723 · Cited by 41
Self-citationTena, I., Gupta, G., Tajahuerce, M., Benavent, M., Cifrián, M., Falcón, A., Fonfría, M., Olmo-García, M. I. D., Reboll, R., Conde-Moreno, A. J., et al. (2018) · Clinical Medicine Insights Oncology · doi:10.1177/1179554918763367 · Cited by 34
Reibetanz, J., Rinn, B., Kunz, A. S., Flemming, S., Ronchi, C. L., Kroiß, M., Deutschbein, T., Pulzer, A., Hahner, S., Kocot, A., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6999-z · Cited by 32
Claps, M., Cerri, S., Grisanti, S., Lazzari, B., Ferrari, V. D., Roca, E., Perotti, P., Terzolo, M., Sigala, S., & Berruti, A. (2017) · Endocrine · doi:10.1007/s12020-017-1428-9 · Cited by 31
Self-citationPorpiglia, F., Fiori, C., Daffara, F., Zaggia, B., Ardito, A., Scarpa, R. M., Papotti, M. G., Berruti, A., Scagliotti, G. V., & Terzolo, M. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0422-4 · Cited by 23
Self-citationLack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma
Sue, M., Martucci, V. L., Frey, F., Lenders, J. W. M., Timmers, H. J. L. M., Pęczkowska, M., Prejbisz, A., Brede, S., Bornstein, S. R., Arlt, W., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0756 · Cited by 18
Self-citationAn Update on the Histology of Pheochromocytomas: How Does it Relate to Genetics?
Oudijk, L., Gaal, J., Koopman, K., & de Krijger, R. R. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0672-1266 · Cited by 7
Cited by
Fassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
Self-citationPersonalized Management of Pheochromocytoma and Paraganglioma
Nölting, S., Bechmann, N., Taieb, D., Beuschlein, F., Fassnacht, M., Kroiss, M., Eisenhofer, G., Grossman, A., & Pacak, K. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab019 · Cited by 417
Self-citationApproach to the Patient With Adrenal Incidentaloma
Bancos, I., & Prete, A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab512 · Cited by 201
Metadata
- Authors
- Fassnacht, M., Assie, G., Baudin, E., Eisenhofer, G., de la Fouchardiere, C., Haak, H. R., de Krijger, R., Porpiglia, F., Terzolo, M., & Berruti, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 31
- Issue
- 11
- Pages
- 1476-1490
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3081691533
- Cited by
- 436
- References
- 87
- FWCI
- 39.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.